Active Filter(s):
Details:
The study, which enrolled approximately 150 patients, is a randomized, placebo‑controlled study to evaluate the safety, efficacy, and pharmacodynamics of volagidemab at 35 mg and 70 mg in type 1 diabetes patients who are currently receiving insulin treatment.
Lead Product(s): Volagidemab
Therapeutic Area: Endocrinology Product Name: REMD-477
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021